Dear John,

Thanks for reading Health Affairs Today.

We will be taking Monday off in observance of the Indigenous Peoples' Day holiday.

We will return to your inbox on Tuesday.

This week, a federal appeals court unanimously upheld Medicare’s drug price negotiation program by rejecting Novo Nordisk’s challenge.

For Flashback Friday, let's take a closer look at what Health Affairs has published on the topic of drug pricing.

Trends In Authorized Generic Drug Launches And Their Effects On Competition In Oral-Solid Drug Markets In The US, 2016–23

Keith M. Drake et al. (June 2025)

Estimated Savings From Extending Prescription Drug Inflationary Rebates To All Commercial Plans

Marissa B. Reitsma et al. (March 2025)

Blockbusters And Loopholes: Expanding Exemptions In Medicare Drug Price Negotiations

Kristi Martin et al. (August 2025)

part of our Health Policy At A Crossroads series

Administration Lays Out Drug Pricing Plan Through Executive Order

Rachel Sachs (April 2025)

part of our Health Policy At A Crossroads series

What Medicare Negotiation Tells Us About Drug Pricing In The U.S.

Jennifer C. Chen et al. (September 2024)

Today's Featured Articles

Future of Primary Care: Bright or Broken? w/ Troyen Brennan

Health Affairs' Jeff Byers welcomes Troyen A. Brennan of Harvard T.H. Chan School of Public Health and former CMO at CVS Health to the pod to discuss his new book, Wonderful and Broken: The Complex Reality of Primary Care in the United States.

The 'Patients Deserve Price Tags' Act Would Empower Employers With Information—Is That Enough?

Karen Handorf et al.

part of our Provider Prices In The Commercial Sector series

As An Alternative To Federal Research Funding, Private Investment Brings Significant Risks

Daniel G. Aaron and Michael S. Sinha